Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12.
Shiozawa T, Sekine I, Aida Y, Watanabe H, Nakazawa K, Kurishima K, Satoh H, Hizawa N. Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer. Case Rep Oncol. 2018 Sep 7;11(3):622-632.
Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I. Augmented antitumor activity of 5-FU by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells. Cancer Sci. 2018 Nov 29.
Imanishi M, Yamamoto Y, Hamano Y, Yamada T, Moriwaki T, Gosho M, Okumura T, Boku N, Kondo H, Hyodo I. Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. Eur J Cancer. 2018 Nov 21;106:69-77.
Yamaura M, Yamada T, Watanabe R, Kawai H, Hirose S, Tajima H, Sato M, Uchida Y, Suganuma D, Yamamoto Y, Moriwaki T, Hyodo I. Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report. BMC Cancer. 2018 Nov 20;18(1):1142.
Nakao T, Fukushima H, Fukushima T, Suzuki R, Hosaka S, Yamaki Y, Kobayashi C, Iwabuchi A, Imagawa K, Sakai A, Shinkai T, Masumoto K, Sakashita S, Masumoto T,Mizumoto M, Sumazaki R, Sakurai H. Interinstitutional patient transfers between rapid chemotherapy cycles were feasible to utilize proton beam therapy for pediatric Ewing sarcoma family of tumors. Rep Pract Oncol Radiother. 2018 Sep-Oct;23(5):442-450.
Ohki K, Kiyokawa N, Saito Y, Hirabayashi S, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, Yoshimi A, Ogata-Kawata H, Sakamoto H, Kato M, Fukushima K, Hasegawa D, Fukushima H, Imai M, Kajiwara R, Koike T, Komori I, Matsui A, Mori M, Moriwaki K, Noguchi Y, Park MJ, Ueda T, Yamamoto S, Matsuda K, Yoshida T, Matsumoto K, Hata K, Kubo M, Matsubara Y, Takahashi H, Fukushima T, Hayashi Y, Koh K, Manabe A, Ohara A. Clinical and molecular characteristics of MEF2D fusion-positive precursor B-cell acute lymphoblastic leukemia in childhood,including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. Haematologica. 2018 Aug 31. pii: haematol.2017.186320.
2017年
Sekine I. Case reports of adverse drug reactions associated with nivolumab administration. Jpn J Clin Oncol. 2017 Feb 16:1.
Sekine I. What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer? J Thorac Dis. 2017 May;9(5):E447-E450.
Sekine I, Harada H, Yamamoto N, Wakabayashi M, Murakami H, Goto K, Nogami N, Seto T, Oshita F, Okamoto H, Tanaka H, Tamura T, Ishikura S, Ohe Y. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011). Lung Cancer. 2017 Jun;108:232-237.
Fujita K, Morishima Y, Aida Y, Tsunoda Y, Hida N, Shiozawa T, Nakazawa K, Sekine I, Hizawa N. Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report. J Thorac Oncol. 2016 Oct 22. pii: S1556-0864(16)31174-1.
Tanaka R, Fujisawa Y, Sae I, Maruyama H, Ito S, Hasegawa N, Sekine I, Fujimoto M. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Jpn J Clin Oncol. 2017 Feb 11;47(2):175-178.
Ashinuma H, Shingyoji M, Yoshida Y, Itakura M, Iizasa T, Sakashita Y, Sekine I. Retrospective analysis of lung cancer patients treated with supportive care alone. Int J Clin Oncol. 2017 Jan 31.
Sakaida E, Ebata T, Iwasawa S, Kurimoto R, Yonemori S, Ota S, Nakatani Y, Sekine I, Takiguchi Y. Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma. Intern Med. 2017;56(5):567-570.
Shimazu K, Tada Y, Morinaga T, Shingyoji M, Sekine I, Shimada H, Hiroshima K, Namiki T, Tatsumi K, Tagawa M. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. BMC Cancer. 2017 May 2;17(1):309.
Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017 Aug 1;47(8):678-682.
Tachi H, Shiozawa T, Sakai C, Kasuga M, Nakazawa K, Morishima Y, Satoh H, Hizawa N, Sakashita S, Sekine I. Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia. J Thorac Oncol. 2017 Aug;12(8):e118-e120.
Tajiri K, Aonuma K, Sekine I. Cardiovascular toxic effects of targeted cancer therapy. Jpn J Clin Oncol. 2017 Sep 1;47(9):779-785.
Iwamoto K, Ishitsuka Y, Tanaka R, Sekine I, Fujimoto M. Iwamoto K, Ishitsuka Y, Tanaka R, Sekine I, Fujimoto M. Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. Eur J Dermatol. 2017 Jun 1;27(3):301-303.
Yamauchi S, Zhong B, Kawamura K, Yang S, Kubo S, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes. BMC Cancer. 2017 Sep 5;17(1):622.
Morinaga T, Nguyễn TTT, Zhong B, Hanazono M, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced. Virol J. 2017 Nov 10;14(1):219.
Qin Y, Sekine I, Fan M, Takiguchi Y, Tada Y, Shingyoji M, Hanazono M, Yamaguchi N, Tagawa M. Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells. Cancer Cell Int. 2017 Dec 11;17:120.
Suzuki H, Sasada M, Kamiya S, Ito Y, Watanabe H, Okada Y, Ishibashi K, Iyoda T, Yanaka A, Fukai F. The Promoting Effect of the Extracellular Matrix Peptide TNIIIA2 Derived from Tenascin-C in Colon Cancer Cell Infiltration. Int J Mol Sci. 2017 Jan 17;18(1). pii: E181.
Matano D, Moriwaki T, Tange Y, Niisato Y, Yamaura M, Nagase M, Suganuma D, Takagi Taketa K, Iwai K, Enami C, Yamamoto Y, Hyodo I. Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination. Intern Med. 2017;56(8):921-923.
Fukushima H, Nanmoku T, Hosaka S, Yamaki Y, Kiyokawa N, Fukushima T, Sumazaki R. The Partial Duplication of the 5′ Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia. Case Rep Pediatr. 2017;2017:6257494.
Fukushima H, Fukushima T, Suzuki R, Iwabuchi A, Hidaka K, Shinkai T, Masumoto K, Muroi A, Yamamoto T, Nakao T, Oshiro Y, Mizumoto M, Sakurai H, Sumazaki R. Comorbidity and quality of life in childhood cancer survivors treated with proton beam therapy. Pediatr Int. 2017 Oct;59(10):1039-1045.
2016年
Sekine I, Sumi M, Satouchi M, Tsujino K, Nishio M, Kozuka T, Niho S, Nihei K, Yamamoto N, Harada H, Ishikura S, Tamura T. Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer. Cancer Sci. 2016 Jan 7.
Sekine I. Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites? J Thorac Dis. 2016 Nov;8(11):E1517-E1519.
Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H, Sekine I, Takiguchi Y, Tatsumi K, Tagawa M. An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol. Springerplus. 2016 Feb 27;5:195.
Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T, Sekine I, Tada Y, Tatsumi K, Takiguchi Y. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study. Jpn J Clin Oncol. 2016 Jan 10. pii: hyv203.
Niho S, Nokihara H, Nihei K, Akimoto T, Sumi M, Ito Y, Yoh K, Goto K, Ohmatsu H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Ohe Y, Tamura T. Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients with Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites. Am J Clin Oncol. 2016 Apr;39(2):132-5.
Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol. 2016 May;48(5):1825-36.
Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer. 2016 Sep;24(9):4025-33.
Jiang Y, Zhong B, Kawamura K, Morinaga T, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma. BMC Cancer. 2016 Jul 12;16(1):455.
Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, Okune M, Inoue S, Sekine I, Tamaoka A, Fujimoto M. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. Jpn J Clin Oncol. 2016 Sep;46(9):875-8.
Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016 Mar 16;1(2):e000037.
Moriwaki T, Yamamoto Y, Gosho M, Kobayashi M, Sugaya A, Yamada T, Endo S, Hyodo I. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. Br J Cancer. 2016 Apr 12;114(8):881-8.
Yamada T, Yamamoto Y, Moriwaki T, Hyodo I. Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer? J Gastroenterol. 2016 May;51(5):506-7.
Kudo M, Yamamoto Y, Koga Y, Hamaguchi T, Akimoto T, Yasunaga M, Matsumura Y. Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts. Mol Clin Oncol. 2016;5:817-822.
Sugaya A, Hyodo I, Koga Y, Yamamoto Y, Takashima H, Sato R, Tsumura R, Furuya F, Yasunaga M, Harada M, Tanaka R, Matsumura Y. Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect. Cancer Sci. 2016 Mar;107(3):335-40.
Suzuki H, Fukushima H, Suzuki R, Hosaka S, Yamaki Y, Kobayashi C, Sakai A, Imagawa K, Iwabuchi A, Yoshimi A, Nakao T, Kato K, Tsuchida M, Kiyokawa N, Koike K, Noguchi E, Fukushima T, Sumazaki R. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. J Hum Genet. 2016 Sep;61(9):797-801.
2015年
Kurimoto R, Sekine I, Iwasawa S, Sakaida E, Tada Y, Tatsumi K, Takahashi Y, Nakatani Y, Imai C, Takiguchi Y. Alveolar hemorrhage associated with pemetrexed administration. Intern Med. 2015;54(7):833-6
Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs. 2015 May 1.
Ma G, Zhong B, Okamoto S, Jiang Y, Kawamura K, Liu H, Li Q, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. A combinatory use of adenoviruses expressing melanoma differentiation-associated gene-7 and replication-competent adenoviruses produces synergistic effects on pancreatic carcinoma cells. Tumour Biol. 2015 ; 36(10):8137-45.
Yang S, Kawamura K, Okamoto S, Yamauchi S, Shingyoji M, Sekine I, Kobayashi H, Tada Y, Tatsumi K, Hiroshima K, Shimada H, Tagawa M. Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression. BMC Cancer. 2015 Jun 10;15:464.
Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 2015 Sep;89(3):287-93.
Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, Ohe Y. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer. Jpn J Clin Oncol. 2015 Jul 31. pii: hyv107.
Yamauchi S, Kawamura K, Okamoto S, Morinaga T, Jiang Y, Shingyoji M, Sekine I, Kubo S, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma. Apoptosis. 2015 Dec;20(12):1587-98.
Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I, Tatsumi K, Tagawa M. A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. Springerplus. 2015 Jul 16;4:358.
Takei Y, Okamoto S, Kawamura K, Jiang Y, Morinaga T, Shingyoji M, Sekine I, Kubo S, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Yamaguchi N, Tagawa M. Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells. Cancer Gene Ther. 2015 Sep;22(9):445-53.
Suzuki H, Roa JC, Kawamoto T, Ishige K, Wistuba II, Li D, Thomas MB, Shoda J. Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. Mol Clin Oncol. 2015 May;3(3):464-470.
Yamamoto Y, Hyodo I, Koga Y, Tsumura R, Sato R, Obonai T, Fuchigami H, Furuya F, Yasunaga M, Harada M, Kato Y, Ohtsu A, Matsumura Y. Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. Cancer Sci. 2015 May;106(5):627-34.
Tsumura R, Sato R, Furuya F, Koga Y, Yamamoto Y, Fujiwara Y, Yasunaga M, Matsumura Y. Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool. Int J Oncol. 2015;47:2107-14.
Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. International Journal of Cancer. 2015;137:1457-66.
Takizawa D, Oshiro Y, Mizumoto M, Fukushima H, Fukushima T, Sakurai H. Proton beam therapy for a patient with large rhabdomyosarcoma of the body trunk. Ital J Pediatr. 2015 Nov 16;41:90.
Fukushima H, Fukushima T, Sakai A, Suzuki R, Kobayashi C, Oshiro Y, Mizumoto M, Hoshino N, Gotoh C, Urita Y, Komuro H, Kaneko M, Sekido N, Masumoto K, Sakurai H, Sumazaki R. Tailor-made treatment combined with proton beam therapy for children with genitourinary/pelvic rhabdomyosarcoma. Rep Pract Oncol Radiother. 2015 May-Jun;20(3):217-22.
Suzuki R, Fukushima H, Noguchi E, Tsuchida M, Kiyokawa N, Koike K, Ma E, Takahashi H, Kobayashi C, Nakajima-Yamaguchi R, Sakai A, Saito M, Iwabuchi A, Kato K, Nakao T, Yoshimi A, Sumazaki R, Fukushima T. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia. Pediatr Int. 2015 Aug;57(4):572-7.
Suzuki R, Kobayashi C, Sakai A, Fukushima H, Tagawa M, Satomi K, Nanmoku T, Sumazaki R, Fukushima T. Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2015 Aug;37(6):e368-71.
Mizumoto M, Oshiro Y, Takizawa D, Fukushima T, Fukushima H, Yamamoto T, Muroi A, Okumura T, Tsuboi K, Sakurai H. Proton beam therapy for pediatric ependymoma. Pediatr Int. 2015 Aug;57(4):567-71.
Mizumoto M, Oshiro Y, Ayuzawa K, Miyamoto T, Okumura T, Fukushima T, Fukushima H, Ishikawa H, Tsuboi K, Sakurai H. Preparation of pediatric patients for treatment with proton beam therapy. Radiother Oncol. 2015 Feb;114(2):245-8.
Tanaka Y, Manabe A, Fukushima H, Suzuki R, Nakadate H, Kondoh K, Nakamura K, Koh K, Fukushima T, Tsuchida M, Koike K, Kiyokawa N, Noguchi E, Sumazaki R, Komiyama T. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Aug;15(4):380-4.
